Abstract: A device for storing a discrete quantity of liquid for use in a primary medical syringe for a bolus injection. The device comprises a body member having a core member inserted in the reservoir of the primary syringe. A liquid passageway for storing a radionuclide for the bolus injection is formed by a helical groove around the core member. A secondary syringe may be included in the primary syringe to measure small quantities of injectate.

Abstract: .sup.166 Holmium in a carrier metallic hydroxide aggregate is disclosed for the treatment of arthritis and, in particular, rheumatoid arthritis. The compound disclosed preferably has a particle size of 1 to 40 microns, Beta energy emissions in the range of 1.76-1.84 MeV, low levels of gamma ray emissions and a radioactive half-life of 26.8 hours. The preferred metallic hydroxide is selected from the group consisting of Ferric Hydroxide, Aluminum Hydroxide, Bismuth Hydroxide, Chromium Hydroxide, Cupric Hydroxide, Manganese Hydroxide and Stannous Hydroxide. Methods are also disclosed for the preparation of the compound, as well as for the methods of its administration to a patient in need thereof.

Abstract: A diverging template (18) for radioactive therapy of cancer within an internal tumor volume by interstitial implants through the skin (78) comprises a proximal surface (34) for positioning adjacent the skin and a distal surface (36) opposite the proximal surface (34). An axis (32) of the template (18) is substantially perpendicular to the proximal surface (34). A plurality of holes (24'-30') are formed in the template (18) from the distal surface (36) to the proximal surface (34) for guiding respective needles (24-30) through the skin (78) and into the tumor volume. The holes comprise at least a first group (28) and a second group (26), each hole of the first group (28) spaced from the axis (32) and forming a first angle therewith that diverges from the distal surface (36) to the proximal surafce (34). Each hole (26) of the second group is spaced from the axis (32) and diverges from the distal surface (36) to the proximal surface (34) at a second angle greater than the first angle.

Abstract: Tumors in the body of a patient are studied in situ by a monitor, such as computer assisted tomography, X-ray or the like, while optimal flow paths through the tumor area are established. A catheter with a suction lumen and an infusion lumen, with seals associated with each, is placed in the patient's vein near the tumor. Flow is then sealed in the vein with the infusion seal. A carrier medium dye is injected into the tumor at selected flow rates and differential pressures. Flow of the dye through the tumor is observed on the monitor to determine optimal retrograde perfusion paths through the tumor for the selected flow rates and differential pressures. Once the optimal perfusion paths are noted, a preferential attack area in the tumor is located using a different, less dense carrier dye and increased fluid back pressure in the infusion system.

Abstract: A drivable radioactive source capsule is provided which comprises a tubular body containing therein a plurality of radioactive sources. The said tubular body has a first end and a second end which is a terminus of the tubular body. A plug has an elongated closure portion with the diameter of the closure portion being substantially equal to the inside diameter of said tubular body. The closure portion is disposed within the tubular body through the second end thereof and is attached to the second end of the tubular body. The plug has a connection portion adjacent the closure portion with the diameter of the connecting portion being substantially equal to the outside diameter of the tubular body. An elongated flexible drive cable is connected to the connection portion of the plug.

Abstract: An antibody or antibody fragment is modified by chemical linkage to a synthetic poly(amide/urea/thiourea) which contains a plurality of boron atoms or other functional groups, conferring upon the resultant conjugate desirable properties as a diagnostic and/or therapeutic agent. In a preferred embodiment, boron-containing groups are conjugated to the antibody/fragment such that the resultant conjugate contains 50-2000 boron atoms, with about 96% Boron-10 isotope content, to produce conjugates useful for neutron-activated radiotherapy of tumors or pathological lesions.